Brought to you by 
Cubist gets US co-promotion rights to Optimer's Dificid
01 Aug 2013
Executive Summary
Anti-infectives developer Optimer Pharmaceuticals Inc. has licensed Cubist Pharmaceuticals Inc. (therapies for the acute care market) exclusive US co-promotion rights to its Dificid (fidaxomicin) antibiotic for the treatment of Clostridium difficile infection (CDI) or C. difficile-associated diarrhea (CDAD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com